Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
about
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Vision and vision-related outcome measures in multiple sclerosis.Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknownQuantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
P2860
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alemtuzumab improves contrast ...... -remitting multiple sclerosis.
@en
Alemtuzumab improves contrast ...... -remitting multiple sclerosis.
@nl
type
label
Alemtuzumab improves contrast ...... -remitting multiple sclerosis.
@en
Alemtuzumab improves contrast ...... -remitting multiple sclerosis.
@nl
prefLabel
Alemtuzumab improves contrast ...... -remitting multiple sclerosis.
@en
Alemtuzumab improves contrast ...... -remitting multiple sclerosis.
@nl
P2093
P2860
P356
P1476
Alemtuzumab improves contrast ...... -remitting multiple sclerosis.
@en
P2093
David H Margolin
Jeffrey Palmer
Jennifer Graves
John Bilbruck
Marco Rizzo
P2860
P304
P356
10.1177/1352458513475722
P577
2013-03-04T00:00:00Z